46.30
+0.95(+2.09%)
Currency In CHF
Address
Grenzacherstrasse 487
Allschwil, 4058
Switzerland
Phone
41 61 606 11 11
Website
Sector
Healthcare
Industry
Biotechnology
Employees
164
First IPO Date
March 25, 2004
| Name | Title | Pay | Year Born |
| Mr. David Veitch | Chief Executive Officer | 1.2M | 1965 |
| Dr. Marc Engelhardt M.D. | Chief Medical Officer | 0 | 1964 |
| Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer | 0 | 1967 |
| Dr. Gerrit Hauck Ph.D. | Chief Technology Officer | 0 | 1964 |
| Mr. Andreas Kumin | Head of Corporate Development | 0 | N/A |
| Mr. Adesh Kaul | Chief Financial Officer | 0 | 1974 |
| Mr. Mark Jones Ph.D. | Head of Global Affairs | 0 | 1967 |
| Ms. Ursula Eberhardt | Head of Global Human Resources | 0 | 1962 |
| Dr. Peer Nils Schroder Ph.D. | Head of Corporate Communications & Investor Relations | 0 | N/A |
| Mr. Damian Heller | General Counsel & Corporate Secretary | 0 | 1966 |
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.